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Letter to the EditorSuccessful hematopoietic stem
cell transplantation for
myelofibrosis in an adult with
warts-hypogammaglobulinemia-
immunodeficiency-myelokathexis
syndromeTo the Editor:
Warts-hypogammaglobulinemia-immunodeficiency-myeloka-
thexis (WHIM) syndrome is a rare autosomal-dominant disorder
characterized by severe neutropenia, B-cell lymphopenia, hypo-
gammaglobulinemia, and refractory human papillomavirus
(HPV) infections. Contrasting with the neutropenia, abundant
mature neutrophils with hypersegmented nuclei are retained in
the bone marrow, a phenomenon named myelokathexis. Most
cases of WHIM syndrome are caused by gain-of-function muta-
tions in the C-X-C chemokine receptor type 4 (CXCR4).
CXCR4 was first studied as a cell surface receptor for HIV. The
interaction with its ligand, stromal cell–derived factor 1 or che-
mokine C-X-C motif ligand 12 (CXCL-12), is crucial for bone
marrow homing, myelopoiesis, and lymphopoiesis. The reported
mutations mostly affect the cytoplasmic C-terminal tail of the re-
ceptor, leading to increased production of inositol phosphate and
prolonged ligand-stimulated release of intracellular calcium. This
mechanism provides a rationale for the retention of neutrophils in
the bone marrow.1,2
The prognosis of patients with WHIM syndrome is hampered
by pyogenic infections, the development of lymphoma, and HPV-
related carcinoma, for example, cervical carcinoma and basal cell
carcinoma.3 Fatal disseminatedMycobacterium avium intracellu-
lare infection has also been reported.4 Plerixafor, a small mole-
cule inhibitor of CXCR4 first studied as an anti-HIV drug and
later used as a potent stem cell–mobilizing agent, is a potential
treatment for WHIM syndrome. Interestingly, it is more effective
in increasing peripheral blood lymphocyte numbers than neutro-
phil numbers.5
CXCR4 is expressed in the lung, the adrenal gland, and the
salivary glands. Bone marrow endothelial cells and other stromal
cells have also been shown to express both CXCR4 and its ligand.
However, expression of CXCR4 is strongest on hematopoietic
cells. Therefore, hematopoietic stem cell transplantation (HSCT)
holds promise as a potential long-term treatment. There has been
a single report in the literature of an unrelated cord blood
transplantation in WHIM syndrome, however, with limited
follow-up.6 A recent report on chromothripsis of chromosome 2
in a single hematopoietic stem cell leading to cure paves the
way for gene therapy in WHIM syndrome.7
We report a patient with WHIM syndrome caused by a novel
deletion in the C-terminal domain of CXCR4 complicated by
myelofibrosis and cured by HSCT. The study was approved by the
Ethics Committee of the University Hospitals Leuven; the patient
gave written informed consent to report the case.
The patient presented at the age of 18 years with refractory
cutaneous and genital warts and recurrent cutaneous herpes
simplex virus infection. Her medical history included recurrent
otitis media attributed to neutropenia. Blood analysis revealed
severe neutropenia, B-cell lymphopenia, and hypogammaglobu-
linemia (see Table E1 in this article’s Online Repository atwww.jacionline.org). Bone marrow aspiration and biopsy
together with electron microscopic examination were compatible
with myelokathexis showing abundant hypersegmented neutro-
phils (Fig E1, A) (Fig 1, A-C). Sequencing of CXCR4 revealed
a de novo mutation c.956_957delCT (RefSeq NM_003467.2)
resulting in a frame shift with a premature stopcodon
(NP_003458.1; p.Ser319CysfsX24) in the C-terminal domain of
the receptor (Fig 2).
Treatment consisted of immunoglobulin substitution, G-CSF,
and prophylactic antibiotics. The HPV lesions were treated with
imiquimod, laser therapy, and excision. She was immunized with
Gardasil. G-CSF treatment was not successful in increasing
neutrophil counts and warts persisted. Progressive pancytopenia
was noticed 1.5 years after presentation. New bone marrow
biopsy showed myelofibrosis grade 2/3 (Fig E1, B; Fig 1, D-G).8
There was no evidence of hairy cell leukemia, myelodysplasia, or
chronicmyeloid leukemia. Therewas subtle erythrophagocytosis.
Bone marrow HHV-6 PCR and Parvovirus B19 PCR were nega-
tive. The patient did not carry the JAK2 V617F mutation typical
of primary myelofibrosis and karyotype was normal. Because of
refractory pancytopenia with transfusion dependence and due to
the patient’s wish for definitive cure, HSCTwith peripheral blood
stem cells from a 10/10matched unrelated donor (MUD) was per-
formed following conditioning with ATG 10 mg/kg, treosulfan
14 g/m2, and Fludarabine 150 mg/m2. Graft-versus-host-disease
prophylaxis consisted of cyclosporine and methotrexate. The
graft contained 7.53 106 CD34(1) cells/kg. Engraftment of neu-
trophils (>1.5 3 109/L) and platelets (>50 3 109/L) occurred at
day 16. There was no acute or chronic graft-versus-host-disease.
However, there was a flare of HPV lesions with increase in both
plantar and genital warts and appearance of interdental papillo-
mata treated with imiquimod. Finally, the lesions resolved
completely at 1.5 years post-HSCT.
Bone marrow examination showed disappearance of myelofi-
brosis and normal hematopoiesis without features reminiscent of
WHIM syndrome as early as 1month post-HSCT (Fig E1,C). She
received immunoglobulin substitution until 1 year post-HSCT.
Bone marrow biopsy 1 year post-HSCT was normal (Fig 1, H
and I). Chimerism was full donor at 1 year post-HSCT. Split
chimerism as determined by PCR on cells sorted by
fluorescence-activated cell sorting was full donor in B, T, and nat-
ural killer cells. At latest follow-up, 4 years posttransplant, chime-
rism is still full donor. The patient is off all treatment and mounts
protective antipolysaccharide (antipneumococcal, anti–Haemo-
philus influenzae) and antiprotein antibody responses to immuni-
zation antigens (antitetanus, antipertussis). She has persistent
mild CD4(1) T-cell lymphopenia and partial IgA deficiency
with IgG and IgM in the lower normal range (Table E1). This
incomplete immune reconstitution may well fit in the context of
a MUD donor; alternatively, it may be explained by the preceding
myelofibrosis although scarce data onHSCT inmyelofibrosis pre-
clude definite conclusions. Finally, the expression of CXCR4 on
stromal cells may play a role.
The novel mutation reported most likely results in increased
calcium fluxes, like the reported truncating mutations in the C-
terminal region although we were not able to prove this.
The development of myelofibrosis in this patient is intriguing
and has never been reported in WHIM syndrome.1
FIG 1. WHIM syndrome patient’s bone marrow trephine findings at presentation, at diagnosis of
myelofibrosis, and post-HSCT. A-C, Histological section of the bone marrow trephine (a hematoxylin-
eosin [HE] stain at 6303) at diagnosis shows normal cellularity and normal distribution of the 3 hematopoi-
etic lineages with a prominent myeloid lineage with aberrant hyperlobulation in the granulocytes,
confirmed by transmission electron microscopy (Fig 1, B, 30,0003). A moderate degree of erythrophagocy-
tosis is present (Fig 1, C, immunohistochemistry against CD68, 6303).D-G, Histological staining of the bone
marrow trephine (Fig 1, E and F, HE stain at 503 and 4003, respectively) in the context of pancytopenia
shows an increased cellularity, the intertrabecular fat being replaced by an overrepresented myeloid series.
The myeloid series is composed of a mixture of prominent neutrophils in conjunction with focal groups of
myeloid precursors, contained within grade 2/3 myelofibrosis according to Tefferi et al8 (Fig 1, F, reticulin
silver staining, 4003). The megakaryocytes are inconspicuous and the erythroid series are organized in
erythroid islands. CD34(1) blasts are not increased (Fig 1, G, immunohistochemistry, 4003). H and I, Histo-
logical staining of the bone marrow biopsy 1 y post-HSCT showing normalization of cellularity and marrow
composition after stem cell transplantation (Fig 1,H and I, HE 503, HE 4003, respectively). (Scale bars A, C-I:
50 mm; B: 1.5 mm.)
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CXCR4 expression was noted in primary myelofibrosis.9 There
are some reports to show that CXCR4-CXCL-12 signaling
directly activates JAK2 signaling cascades, leading to Ras/Raf-
MAPK and PI3K/Akt activation and resulting in cell prolifera-
tion.10 Also, in tumor cells, increased CXCL-12/CXCR4
signaling has been shown to lead to inhibition of apoptosis via
altered nuclear factor kappa B and BCL2 signaling.11 Because
WHIM syndrome is usually caused by CXCR4 gain-of-function
mutations, this may lead to increased JAK2 signaling with
increased proliferation. Most patients with primary myelofibrosis
carry the activating mutation JAK2 (V617F); in this context,
exactly the same pathways (MAPK-PI3K/Akt) are upregulated.
Thus, we hypothesize that enhanced CXCR4/CXCL-12 signalingas in WHIM syndrome may result in a phenocopy of the JAK2
gain-of-function mutation in primary myelofibrosis. Although
the exact role of activating CXCR4 mutations in the development
of myelofibrosis is at present unstudied, we speculate that fibrosis
may be an additional explanation for the neutropenia/pancyto-
penia sometimes observed in WHIM syndrome. Because not all
features ofWHIM are as penetrant as neutropenia, it seems appro-
priate to consider the underlying WHIM syndrome in any patient
presenting with primary myelofibrosis especially because stan-
dard treatment of the myelofibrosis with JAK-2 inhibitors may
be hazardous.
We illustrate that WHIM syndrome can be cured by HSCT.
Follow-up data 4 years post-HSCT are provided. Importantly,
during the preengraftment phase and until partial lymphocyte
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FIG 2. Indication of the mutation in the C-terminal domain of CXCR4 in relation to other mutations
described in CXCR4. The mutation reported here is indicated in red. Within the C-terminal domain, red dots
denote the positions of previously reported mutations. Threonine is represented by a black triangle, serine
by a green hexagon. Other amino acids are represented by red dots. Figure modified from Al Ustwani et al.2
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and cutaneous warts and condylomata. However, with T cells
rising, the warts and condylomata subsided. Four years post-
HSCT, chimerism is full donor. Moreover, bone marrow exam-
ination at 1 year post-HSCT was normocellular and free of
myelofibrosis.
At the time of HSCT, plerixafor was not available, sowe cannot
hypothesize on the potential cure of myelofibrosis by plerixafor
treatment. Given the risks of mortality and morbidity associated
with HSCTand the absence of major side effects in the first trials,
a trial with plerixafor is likely to be indicated. Indeed, it has been
shown that daily intramuscular plerixafor injections resulted in
substantial increases in both peripheral blood lymphocyte and
neutrophil numbers (although even at the highest doses the
neutrophil counts never normalized). However, the long-term
risks and benefits of plerixafor treatment in WHIM syndrome are
unknown, especially in the context of myelofibrosis. Moreover,
WHIM syndrome carries a substantial risk of potentially fatal
infection and of development of lymphoma and cancerous skin/
genital lesions. It is not clear at this point how penetrant these
features are in WHIM syndrome and to what extent long-term
plerixafor therapy will be protective in this context. Clearly, the
merits and risks of different therapeutic options should beconsidered for the management of each individual case. The
data presented in this report are encouraging for a definitive cure
by HSCT.
In conclusion, we describe the development of pancytopenia
due to myelofibrosis in a patient with WHIM syndrome, caused
by a novel mutation affecting the C-terminal domain of the
intracellular part of the CXCR4 receptor. Moreover, we report the
successful outcome following HSCT from a 10/10 MUD. Four
years post-HSCT she is off all treatment.
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FIG E1. A, Bone marrow aspirate stained with May-Gr€unwald-Giemsa
showing hypersegmented neutrophils (3100). B, Bone marrow aspirate
showing a hypocellular bone marrow with teardrop cells consistent with
myelofibrosis (350, May-Gr€unwald-Giemsa stain). C, Bone marrow aspi-
rate shows normal hematopoiesis at 1 month post-HSCT (3100 May-
Gr€unwald-Giemsa stain).
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TABLE E1. Peripheral blood cell count, immunoglobulin levels, and immunophenotyping at diagnosis and at latest follow-up 4 years
post-HSCT
Stage ANC (3 109/L) ALC (3 109/L) AMC (3 109/L) Hemoglobin (g/dL) Platelet (3 109/L) IgG (g/L) IgA (g/L) IgM (g/L)
At diagnosis 0.59 0.6 0.3 13.3 308 5.7 0.53 0.62
At latest follow-up 2.60 1.5 0.5 13.9 201 7.68 0.62 0.55
Normal range 2.5-7.8 1.2-3.6 0.2-0.8 12-16 150-450 7.5-15.6 0.82-4.5 0.46-3.0
Stage CD19(1) (3 109/L) CD3(1) (3 109/L) CD4(1) (3 109/L) CD8(1) (3 109/L)
CD3(2)/CD56(1) and/or
CD16(1) (3 109/L)
At diagnosis 0.025 0.424 0.308 0.089 0.125
At latest follow-up 0.254 1.071 0.443 0.474 0.119
Normal range 0.082-0.476 0.798-2.823 0.338-0.079 0.219-1.124 0.075-0.838
Values in boldface are outside the normal range. Lymphocyte proliferation with PHA stimulation index 619.
CD(31)CD27(1)CD45RA(1) T cells: 30% of CD31 T cells.
ANC, Absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count.
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